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AbstrAct
Recent randomised trials on screening with low-dose 
CT have shown important reductions in lung cancer 
(LC) mortality and have triggered international efforts to 
implement LC screening. Detection rates of stage I LC with 
volume CT approaching 70% have been demonstrated. 
In April 2019 ‘ESMO Open – Cancer Horizons’ convened 
a roundtable discussion on the challenges and potential 
solutions regarding the implementation of LC screening in 
Europe. The expert panel reviewed the current evidence 
for LC screening with low-dose CT and discussed the 
next steps, which are covered in this article. The panel 
concluded that national health policy groups in Europe 
should start to implement CT screening as adequate 
evidence is available. It was recognised that there are 
opportunities to improve the screening process through 
‘Implementation Research Programmes’.
IntroduCtIon
Recent large randomised trials on low-dose 
CT screening, including the American 
National Cancer Institute-sponsored National 
Lung Screening Trial (NLST) as well as the 
Dutch/Belgian NELSON (Nederlands-Leu-
vens Longkanker Screenings Onderzoek) 
trial, have shown significant reductions in 
lung cancer (LC) mortality of 20%–26% and 
have triggered international efforts to imple-
ment LC screening.1–3 As demonstrated by 
the results from the International Early Lung 
Cancer Action Project (I-ELCAP) and the 
NELSON clinical trials groups, detection 
rates of stage I LC with volume CT could 
approach 70%.
In April 2019 ‘ESMO Open – Cancer 
Horizons’ convened a roundtable discus-
sion on the challenges and potential solu-
tions regarding the implementation of LC 
screening in Europe. The expert panel 
reviewed the current evidence for LC 
screening with low-dose CT and discussed the 
next steps, which are covered in this article.
Figure 1 shows levels of evidence for imple-
mentation of LC screening in Europe.
recruitment for national LC screening 
programmes
The aim regarding recruitment for national 
LC screening programmes is to achieve an 
informed participation focusing on high-
risk (hard-to-reach) individuals. Those at 
highest risk of LC are those who are most 
likely to benefit from screening (even when 
considering comorbidity); however, they are 
less likely to participate in LC screening and 
are more likely to be of lower socioeconomic 
background and to be current smokers.4
recruitment challenges
Screening approaches
It is a difficult balance between the availability 
of systematic risk data of a relatively large 
group of approachable individuals (health 
registers, primary care registers, question-
naires, online surveys) and ensuring equity, 
versus the less systematic and less costly 
approaches for smaller groups, which are 
likely to be the worried well (through clinics 
and advertising).
Age
It has been argued whether to start recruit-
ment at age 60 or 55. Screening strategies 
for Switzerland indicate a starting age of 60 
and include those up to 79 years of age. The 
National Health Service (NHS) England 
Protocol,5 however, argues for screening 
between 55 and 75 years of age. A number of 
risk prediction models have been developed, 
of which the Prostate, Lung, Colorectal and 
Ovarian Cancer Screening Trial (PLCO)2012
6 
(1.6% risk over 6 years) and the Liverpool 
Lung Project (LLP)v2
7 8 (2.5% risk over 5 
years) have both been included in the recent 
NHS England Protocol.
In the USA, the US Preventive Services 
Task Force9 on LC screening has a much less 
stringent selection criteria, which is based on 
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Figure 1 Levels of evidence for implementation of lung cancer screening in Europe.4 Amended/updated in 2019 from a figure 
published in ref 4 in 2016. Colour codes: green: sufficient evidence; amber: borderline evidence. LDCT, low-dose CT; LLP, 
Liverpool Lung Project; MDT, multidisciplinary team; NELSON, Nederlands-Leuvens Longkanker Screenings Onderzoek; NICE, 
National Institute for Health and Care Excellence; NLST, National Lung Screening Trial; PLCO, Prostate, Lung, Colorectal and 
Ovarian Cancer Screening Trial; QALY, quality-adjusted life year; UKLS, UK Lung Cancer Screening Trial; VDT, volume doubling 
time.
the NLST and the Cancer Intervention and Surveillance 
Modeling Network.10
Smoking
Some consider one basic inclusion question would suffice: 
‘have you ever smoked?’
Information technology
Investment into information technology systems is 
needed to collate patients’ risk data and also to manage 
and monitor LC CT-screened patients. In the UK this has 
recently been amplified by Sir Professor Richards’ interim 
report on UK cancer screening.11
role-out of LC screening in Europe
The roundtable panel recognised that LC screening 
can be initiated in Europe; however, there is room for 
improvement in several areas, and the recommendation 
discussed is provided in figure 2.
LC screening
Radiology protocol
The most recent European protocol for the management 
of CT-detected nodules was published in Lancet Oncology 
in 2017,3 which was developed as a consensus document 
by experts from nine countries within Europe. Using 
volume doubling time (VDT) biomarker reduces invasive 
procedures, biopsies and surgery by tenfold12 compared 
with the NLST data.1
Recently, it has been recognised that new nodules are 
common in follow-up CT scans (3%–13% screenings)13 14 
and comprise a significantly higher LC probability, which 
are at smaller size, thus the recommendation for new 
nodules during the screening process.
These more stringent cut-off values should be 
mandatory:
 ► Negative screen result: <30 mm3 (LC probability 
<1%).
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Figure 2 European implementation trials needed (source: Harry de Koning (PI) Erasmus MC. Towards individually tailored 
invitations, screenings intervals, and integrated co-morbidity reducing strategies in lung cancer screening (acronym: 4-IN-THE-
LUNG-RUN). European Research Council; H2020-SC1-BHC-2018-2020; grant848294; 2019.)
Figure 3 LC CT screening: NLST and Nelson mortality 
data presented at WCLC 2018.2 Source: Data provided by 
de Koning at WCLC 2018.2 21 F, female; LC, lung cancer; 
M, male; NELSON, Nederlands-Leuvens Longkanker 
Screenings Onderzoek; NLST, National Lung Screening 
Trial; WCLC, World Conference on Lung Cancer.
 ► Indeterminate screen result: 30–200 mm3 (LC proba-
bility ~3%).
 ► Positive screen result: >200 mm3 (LC probability 
~17%).
Screening interval
The screening interval, annual versus biennial, has been 
debated in the literature.15–17 Clearly the optimal screen 
intervals should consider using the previous CT screen 
results to estimate LC risk. However, in the light of the 
recent NELSON results given at the World Conference 
on Lung Cancer (WCLC) in 2018,2 the annual screening 
frequency is considered the default until more data 
supporting other approaches may be available. Never-
theless, it is recognised that there is a potential avenue 
to select individuals with a low risk of developing LC 
using their baseline scan, and depending on their 
overall risk profile they could be considered for biennial 
screening.18–20 This would need continued monitoring 
during the screening lifetime of the patient.
Quality assurance
Quality assurance (QA) in CT screening has been poorly 
implemented. Therefore, the prospect of setting up LC 
CT screening imaging core laboratories for QA as well as 
benchmarking the automated CT scan software and post-
processing procedures are attractive options. However 
mature, validated tools for these purposes are not yet 
widely available. In the mean time, there is a preference 
for the delivery of LC screening care in dedicated clinical 
centres of excellence and using virtual central reading of 
the CT scans.
Mortality reduction in women
The NELSON presentation at the WCLC in 20182 provides 
evidence for LC mortality reduction in women (39%–
61%).2 21 In the NLST this figure was 27% for women 
(figure 3). The implication for the higher mortality gain 
in women compared with men is poorly understood and 
requires further investigation.
Prolonged low-dose CT screening
The Multicentric Italian Lung Detection (MILD) trial 
recently evaluated the benefit of prolonged low-dose CT 
screening beyond 5 years, and its impact on overall and 
LC-specific mortality at 10 years.22 MILD prospectively 
randomised 4099 participants, to a screening arm (n ¼ 
2376), with further randomisation to annual (n ¼ 1190) 
or biennial (n ¼ 1186) low-dose CT for a median period 
of 6 years, or a control arm (n ¼ 1723) without interven-
tion.
In the MILD trial, 2005 and 2018 and 39 293 person-
years of follow-up were accumulated. The primary 
outcomes were 10-year overall and LC-specific mortality. 
The low-dose CT arm showed a 39% reduced risk of LC 
mortality at 10 years (HR 0.61; 95% CI 0.39 to 0.95), 
compared with control arm, and a 20% reduction of 
overall mortality (HR 0.80; 95% CI 0.62 to 1.03). The 
MILD trial provides further evidence that prolonged 
screening beyond 5 years can enhance the benefit of early 
detection and achieve a greater overall and LC mortality 
reduction compared with NLST trial.
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Figure 4 National Optimal Lung Cancer Pathway for suspected and confirmed LC: referral to treatment 2017 V.2 update 
produced by the Clinical Expert Group for Lung Cancer; NHSE, National Health Service England; CXR, chest X-ray; GP, 
general practitioner; LC, lung cancer; MDT, multidisciplinary team; NICE, National Institute for Health and Care Excellence; 
PET, positron emission tomography.
Secondary care pathways: uK protocols to assist the 
implementation of LC screening
The UK National Optimal Lung Cancer Pathway 
(NOLCP) is a timed secondary care pathway approved by 
NHS England (figure 4).
Key features of the early part of the NOLCP include 
recommendations for rapid access to a CT of the thorax 
(within 72 hours of referral or chest radiograph) and a 
subsequent triage process. The latter stratifies patients 
with suspicious CT findings into fast-track cancer clinics, 
with subsequent rapid investigations for and manage-
ment of LC, or appropriately diverts others from cancer 
pathways into alternative services. This includes the 
management of pulmonary nodules according to the 
British Thoracic Society guideline.23
The integration of the NOLCP with CT screening 
provides an opportunity to transform care, as it maxi-
mises the benefits of each and ensures that optimal care 
is provided to patients throughout their clinical pathway. 
The current UK cancer waiting times and unwarranted 
variations in care reflect systemic problems in organisa-
tional process and capacity. Thus, this must be driven 
nationally with regional and local coordination of funding 
and services.
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Multidisciplinary clinics: planning for long-term treatment of 
Ct-screened patients with LC
It is important that medical oncologists are part of the 
long-term treatment planning of CT-screened patients 
with a diagnosis of LC; the same is true for radiologists, 
pulmonologists, surgeons, nuclear medicine physicians 
and cancer nurses. A critical member of the team is the 
smoking cessation counsellor, as the enhanced feedback 
associated with annual attention to smoking cessation 
seems to enhance quit rates. The cost of medical care 
in older smokers can be significantly reduced (by about 
one-third) by inclusion of best practice smoking cessation 
advice24–26 and greatly enhance the cost utility of this inte-
grated screening service.
Large-scale implementation of LC screening within 
nationwide screening programmes in Europe will signifi-
cantly change the landscape of treatment strategies for 
patients due to earlier diagnosis. Hopefully, fewer patients 
with advanced stages will need more palliative approaches 
with systemic treatment (chemotherapy, chemoimmuno-
therapy, immunotherapy), but more patients may need 
adjuvant and consolidation systemic treatments (stages II 
and III, chemotherapy, immunotherapy). Furthermore, 
conversations should also be starting on how to use best 
practice guidelines to manage the large number of asymp-
tomatic screening subjects who will be found to have objec-
tive evidence of chronic obstructive pulmonary disease or 
advanced coronary calcifications. Important trials in the 
Netherlands25 and China are already exploring this crit-
ical new avenue of public health investigation.
Medical oncologists may also need to shift their interest 
from the approaches to advanced disease to ‘multidisci-
plinary approaches’ of stages II, IIIA, IIIB and IVA of LC. 
Further clinical trials with systemic treatments for very 
early LC stages (immunotherapy, chemoimmunotherapy, 
targeted therapy) can be foreseen. As new cancer precur-
sors are detected within the screening population, a new 
generation of chemoprevention trials can be expected. 
This could potentially include immunological manipula-
tion of the early cancer development process.
LC biomarkers in early LC detection
The ‘holy grail’ in biomarker research is to identify other 
early detection biomarker(s) beyond the above-discussed 
imaging biomarkers. Despite a massive investment of 
resources, non-imaging biomarkers have had limited 
success. A recent systematic review on serum and blood-
based biomarkers for LC screening provided an excellent 
update of this topic.27 It evaluated the diagnostic perfor-
mance of EarlyCDT-Lung (an antibody-based biomarker 
screening panel), microRNA (miRNA) signature classi-
fier (a plasma-based 24 miRNA risk score) and miR-test (a 
serum-based 13 miRNA signature), and their impact on 
LC-related mortality and all-cause mortality. Three phase 
III studies were identified, and all three biomarker assays 
show promise for the detection of LC. However, there 
was a lack of definitive evidence to justify integration into 
clinical practice.
Seijo and colleagues28 have recently proposed a number 
of principles to optimise LC biomarker discovery projects. 
They provided an overview of promising molecular candi-
dates, such as autoantibodies, complement fragments, 
miRNAs, circulating tumour DNA, DNA methylation, 
blood protein profiling, and RNA airway or nasal signa-
tures. The emerging biomarkers include exhaled breath 
biomarkers, metabolomics, sputum cell imaging, genetic 
predisposition studies and the integration of next-gener-
ation sequencing into the study of circulating DNA. All 
of these need to be considered in the scope of future 
implementation research in LC screening, together with 
imaging, radiomics and artificial intelligence.29
recent innovative research programmes: which can impact 
on future LC screening implementation research?
Early Lung Imaging Confederation
Since the global implementation of LC screening is only 
starting just now, there has not been the time nor the 
resources so far to create specialised imaging tools to 
enable easy and rapid LC screening management. The 
Quantitative Imaging Biomarkers Alliance organised 
by the Radiological Society of North America has been 
working to define scalable solutions to ensure robust and 
accurate use of volumetric CT imaging to guide screening 
work-up,30 as already published in the UK Lung Cancer 
Screening Trial (UKLS)8 and NELSON trial.3 Large 
collections of thoracic CT images with known clinical 
outcomes are urgently needed to develop and validate LC 
imaging management tools.31
The International Association for the Study of Lung 
Cancer (IASLC) is committed to developing a large 
collection of thoracic CT images to address this bottle-
neck.32 The IASLC with a large multidisciplinary team has 
begun to develop the Early Lung Imaging Confederation 
(ELIC). The goal is to make this cloud-based image collec-
tion/research resource accessible to all IASLC investiga-
tors as well as others, as an open resource to accelerate 
the development of imaging and other tools to manage 
early LC.
Institute for Diagnostic Accuracy Management System
The Institute for Diagnostic Accuracy (iDNA) Manage-
ment System has been developed from the NELSON and 
UKLS screening trial databases.8 12 It is a highly config-
urable client tracking system where clients are screening 
participants (or patients) and where all types of events 
are stored in the client’s history. This client history 
contains all relevant details needed for logistical and data 
management, including features specifically designed 
for LC screening purposes, such as nodule evaluation 
across multiple evaluations and across multiple scan 
moments. This allows central review of CT scans, auto-
mated calculations on VDTs and automated classification 
of screening results (based on the optimised NELSON 
protocol). Second, the software is designed to support 
clear and secure communication between the screening 
site and the screening participants on undertaking LC 
4300.7802.430. Protected by copyright.
 o
n
 O
ctober 31, 2019 at Erasm
us M
edical / X51
http://esm
oopen.bmj.com/
ESM
O
 O
pen: first published as 10.1136/esm
oopen-2019-000577 on 13 O
ctober 2019. Downloaded from
 
Open access
6 Field JK, et al. ESMO Open 2019;4:e000577. doi:10.1136/esmoopen-2019-000577
risk assessment (LLPv2 and PLCO2012), making appoint-
ments, completion of questionnaires (eg, on smoking 
history and informed consent), reporting on screening 
results, integration with email and the use of configurable 
templates for standard notifications and letters. With the 
iDNA Management System all the screening sites’ specific 
needs on data collection, logistics and communication 
can be configured by local administrators, ensuring full 
compliance with local requirements.
Collection of radiological metadata is organised in 
multiple steps and levels, which is based on a direct link 
between the radiologist’s workstation and the iDNA 
Management System: a screening participant can have 
more than one CT scan record; one CT scan record can 
have multiple readings/observations; and one observa-
tion can have multiple nodules and other findings.
The primary application of the iDNA Management 
System is the registration and management of nodules in 
LC screening programmes. The iDNA system has been 
extended with registration and management of calcium 
scores (for cardiovascular diseases),30 33 which can be 
used by collaborative screening sites.34 Other radiological 
features include the validated import of XML (eXtensible 
Markup Language) files generated by local workstations 
directly into the study database.
Other comparable systems are being developed, 
including a collaborative effort between the Veterans 
Administration in the USA working with the I-ELCAP 
with support from the Bristol-Myers Squibb Foundation 
using an open-source software environment.
General data Protection regulation
The recommendation of a European registry for collec-
tion of LC CT screening data was discussed at the round 
table and that the IASLC is exploring options in this 
regard.32 Ideally a registry for screened LC CT images 
should be developed. However, the changing laws around 
the European Union General Data Protection Regulation 
(GDPR) are making this more difficult as it is practically 
impossible to anonymise CT Digital Imaging and Commu-
nications in Medicine images. This is a challenge not just 
within the LC community; it impacts on all radiological 
imaging and needs to be resolved within the European 
Parliament. It would be tragic if reasonable measures to 
ensure personal data protections were to unintention-
ally delay or even block progress in improving curative 
outcomes for Europe’s most lethal adult cancer.
ConCLuSIon
The conclusion reached by the roundtable panel was 
that national health policy groups in Europe should start 
to implement CT screening now as adequate evidence 
is available (figure 1).4 It was recognised that there are 
opportunities to improve the ‘screening process’ through 
‘Implementation Research Programmes’. Areas which 
need specific consideration are around cost-effective-
ness (UKLS data indicate £12 000/quality-adjusted life 
year) and if biennial screening is appropriate for a subset 
of individuals with appropriately delivered integrated 
smoking cessation programmes in place.
overall recommendations
 ► Implementation of LC screening should be a priority 
in Europe. It needs to be driven scientifically, politi-
cally and also using patient advocacy.
 ► Europe needs to plan ‘Implementation Research 
Programmes’.
 ► Investment is needed into recruitment challenges 
especially in ‘hard to reach’ communities.
 ► Ensure thoracic radiologists reporting on CT-screened 
individuals use volume and VDT and are provided 
with the necessary training and work, with QA proce-
dures in place.
 ► The issues around current GDPR need to be resolved, 
in order to enable the development of a European 
registry for collection of LC CT screening data.
 ► Secondary care pathways are aligned with the immi-
nent implementation of LC screening, together 
with service provision and availability of screening 
platforms.
 ► Develop a collegiate approach to the work-up and 
treatment of patients with LC in multidisciplinary 
clinics, identified through CT screening programmes. 
All clinical specialties should be fully engaged, 
including medical oncologists.
 ► The role of non-imaging early detection biomarkers 
is still in an early phase; however, the LC screening 
community should be fully engaged and participate 
in the developing integrated research programmes 
using molecular/radiomics and artificial intelligence 
approaches.
 ► Innovative research programmes (eg, ELIC and 
iDNA) provide enormous potential which can impact 
on LC screening and save lives.
 ► LC CT screening will happen in Europe. It is up to the 
community to make it happen now.
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